Placebo and Side Effects Confound Clinical Trials on New Antitussives

Area of Science:

• Pharmacology
• Clinical Trial Design
• Evidence-Based Medicine

Background:

• Placebo effects related to treatment side effects can confound clinical trials.
• New antitussives, such as ATP antagonists, present unique side effects impacting taste sensation.
• Concerns exist that these side effects may compromise the blinding of clinical trials.

Purpose of the Study:

• To review how placebo effects from side effects confound antitussive clinical trials.
• To examine the implications of taste-altering side effects for ATP antagonist trials.
• To discuss strategies for improving blinding and controlling placebo effects in clinical trials.

Main Methods:

• Review of existing literature on placebo effects and clinical trial methodology.
• Analysis of how side effects can unbalance trial arms and amplify placebo responses.
• Discussion of assumptions like additivity and balance in assessing antitussive pharmacological activity.

Main Results:

• Unblinding due to side effects invalidates efficacy assessments in clinical trials.
• The degree of blinding in clinical trials is rarely assessed, despite its importance.
• Side effects can unbalance trials, amplifying the placebo effect for active treatments.

Conclusions:

• Improving blinding and controlling placebo effects are critical for valid antitussive drug development.
• Proposals include modifying participant information, trial design, patient selection, and using active placebos.
• Urgent attention to trial unblinding is necessary for progress in developing new antitussives.